Catalyst Event

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other

From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)

6/2/2026, 12:00:00 AM

OtherSentiment: Positive

Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).

Korean Translation

2026년 6월 2일 ASCO 연례회의에서 신규 B7-H3 ADC 약물 SKB500의 첫 인체 대상 임상 연구에서 긍정적인 결과를 발표함. 데이터는 다양한 고형암에 걸쳐 광범위한 항종양 활성을 보였으며, 특히 소세포폐암(SCLC)에서 주목할 만한 효능을 나타냄.

Related Recent Events

View Full Timeline